Authors
Latest:
Eva Winnebeck, PhD: Temporal Dynamics of SleepThe postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.
Latest:
Aducanumab's Unlikely Road to the FDA: Is Approval Imminent?Recent news that the FDA has granted the fastest possible review for Biogen’s Alzheimer disease treatment aducanumab may be indicative of the agency’s increasing confidence in the drug.
Latest:
Ways to Align Patient Characteristics of Progressive Multiple Sclerosis Trials With Clinical Reality: Robert J. Fox, MDThe staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed how the CALLIPER trial’s lower proportion of patients with gadolinium-enhancing lesions mirrors clinical practice more closely than other progressive MS trials. [WATCH TIME: 2 minutes]
Latest:
The Changing Landscape of Preventative Migraine TreatmentsA panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.
Latest:
Future Improvements in the Management of NarcolepsyExpert neurologists discuss advancements in the management of narcolepsy including new drug formulations and provide take-home messages for how to improve diagnosis and treatment in the future.
Latest:
Using Prior Success to Improve Alzheimer Trials, Drug Development: Jeffrey Cummings, MD, ScDThe director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada, Las Vegas discussed how the momentum gained within the Alzheimer community can springboard success going forward. [WATCH TIME: 4 minutes]
Latest:
Gill Livingston, MBChB, MD: Challenges of Sleep Difficulties in People Living with DementiaLivingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.
Latest:
Raymond S. Turner, MD, PhD: Safety Results for Nilotinib in AlzheimerThe director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.
Latest:
What You Need to Know About Amantadine for Parkinson DiseaseThis guide includes everything you need to know about amantadine (Osmolex ER, Osmotica Pharmaceuticals) for the treatment of Parkinson disease and drug-induced extrapyramidal reactions in adults.
Latest:
Pouya Ghaemmaghami, PhD: Predicted Gene Expression and the Association with Sleep MacrostructurePreliminary results show that the whole genome information can be used to assess the association between predicted gene expression in different parts of the brain and sleep, suggesting where brain genes are expressed matter for variability in sleep.
Latest:
Eyiyemisi Damisah, MD: Additional Insights Into Cell DeathThe assistant professor of neurosurgery at Yale School of Medicine discussed what doors have been opened by a recent study of the cell death process she and colleagues conducted.
Latest:
Shared Decision-Making in Multiple Sclerosis TreatmentAhmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the need for shared decision-making in MS care.
Latest:
Treatment Gaps Among Elders With Generalized Epilepsy: Vineet Punia, MD, MSThe neurologist at Cleveland Clinic addressed aspects of care for elders with generalized epilepsy that need to be further researched.
Latest:
Expanding the Use of Seizure Apps for Epilepsy: Jessica Fesler, MD, MEdThe staff epileptologist at Cleveland Clinic’s Epilepsy Center discussed new untapped ways seizure apps could help patients with epilepsy. [WATCH TIME: 2 minutes]
Latest:
David Llewellyn, PhD: The Impact of Lifestyle Factors on Genetic Risk in DementiaThe associate professor of neuroepidemiology and digital health spoke about the importance of findings from an observational study which showed that adherence to a healthy lifestyle can offset the genetic risk for dementia.
Latest:
David Leppert, MD: Building a Foundation for Neurofilament LightThe therapeutic head of neuroinflammation and pain at Novartis spoke about his desire to work to a point where physicians can use NfL to monitor disease activity, make therapeutic decisions, and give perspective to patients.
Latest:
Introducing DaxibotulinumtoxinA-Ianm as a Treatment Option for Cervical Dystonia: Peter J. McAllister, MD, FAANThe chief medical officer of New England Center for Neurology and Headache talked about trends observed in the clinical practice with Daxxify, a long-acting botulinum toxin for patients with cervical dystonia. [WATCH TIME: 5 minutes]
Latest:
Sigma-1 Agonists Offer Combination Approach to Dementia SymptomsResearch from the past decade suggests that sigma-1 receptors and their encoding gene, SIGMAR1, together act as a therapeutic target for patients with dementia.
Latest:
Ian Miller, MD: Adapting AAV Gene Therapy for SCN1A-Positive EpilepsyThe medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital discusses his early stage gene therapy trial for Dravet syndrome.
Latest:
Early High-Efficacy TreatmentJames Stankiewicz, MD, provides an overview of the burden of multiple sclerosis and discusses early, high-efficacy treatment of the disease.
Latest:
Peter Calabresi, MD: Utilizing A Uniform Biomarker AssayFor the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.
Latest:
Robert S. Fisher, MD, PhD: Exploring Unanswered Questions in EpilepsyThe Director of the Stanford Epilepsy Center discussed the work that’s left to be done in the field of epilepsy.
Latest:
Geoff Kerchner, MD, PhD: Phase III Trials of Crenezumab in Treatment of Prodromal to Mild AlzheimerData back a 4-fold higher dose of crenezumab in the CREAD 1 and CREAD 2 trials than used in phase II.
Latest:
Targeting the NF-kB Pathway in Duchenne Muscular DystrophyAn in-depth analysis of the genetics of DMD and disease modifiers such as the NF-kB pathway in patients with Duchenne muscular dystrophy.
Latest:
Daniel M. Goldenholz, MD, PhD: Assessing the Risk for SUDEPThe instructor in neurology at Beth Israel Deaconess Medical Center spoke about what clinicians can do right now to mitigate the risk of SUDEP and the myriad of options for them to utilize.
Latest:
World Alzheimer Day 2019: Key Takeaways From Leaders in Alzheimer Disease and DementiaIn recognition of World Alzheimer Day, experts in Alzheimer disease and dementia share insight from the latest Alzheimer Disease International's yearly World Alzheimer Report.
Latest:
Understanding Clinical Predictors of Response to Nabilone in Alzheimer AgitationKrista L. Lanctôt, PhD, professor of psychiatry and pharmacology at the University of Toronto, talked about findings from a recent post hoc analysis presented at CTAD 2024 on nabilone for agitation in Alzheimer disease.
Latest:
Dina Katabi, PhD: Biosensors for Measuring Disease Activity in MS and Other Neurological DisordersThe Andrew & Erna Viterbi Professor of Electrical Engineering and Computer Science at MIT spoke about a new way of continuous monitoring for patients with MS and neurodegenerative disorders, discovering changes in quality of life and new biomarkers.
